Provided by Tiger Fintech (Singapore) Pte. Ltd.

Studio City International Holdings Ltd

3.58
+0.05001.42%
Post-market: 3.580.00000.00%16:04 EDT
Volume:26.90K
Turnover:93.66K
Market Cap:754.36M
PE:-10.03
High:3.63
Open:3.44
Low:3.37
Close:3.53
52wk High:9.30
52wk Low:2.30
Shares:210.72M
Float Shares:17.01M
Volume Ratio:2.77
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3571
EPS(LYR):-0.5022
ROE:-11.87%
ROA:1.21%
PB:1.41
PE(LYR):-7.13

Loading ...

Longeveron Announces Up To $17.5 Million Public Offering

GlobeNewswire
·
Aug 09

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

GlobeNewswire
·
Aug 05

Stock Track | Studio City International Plummets 17.92% as NYSE Halts Trading

Stock Track
·
Aug 04

Nyse Halt Studio City Int Add Info Lst $3.960000

THOMSON REUTERS
·
Aug 04

Stock Track | Studio City International Plummets 6.13% Despite Improved Q2 Earnings and Narrowed Losses

Stock Track
·
Jul 31

Stock Track | Studio City International Holdings Plummets 6.13% Despite Improved Q2 Results

Stock Track
·
Jul 31

Studio City Q2 revenue up 17.7%, narrows net loss

Reuters
·
Jul 31

Studio City Intl Hldgs Q2 Adj earnings per ADS. $(0.017) Up From $(0.165) YoY, Sales $190.051M Up From $161.495M YoY

Benzinga
·
Jul 31

Studio City Q2 Net Income USD -3.7 Million

THOMSON REUTERS
·
Jul 31

Studio City International Holdings Ltd: Q2 Adj EPS $-0.004

THOMSON REUTERS
·
Jul 31

Studio City International Holdings Limited Announces Unaudited Second Quarter 2025 Earnings

THOMSON REUTERS
·
Jul 31

MSC Industrial CFO Kristen Actis-Grande to Step Down

MT Newswires Live
·
Jul 29

Studio City International Holdings Ltd. to Release Second Quarter 2025 Financial Results

Reuters
·
Jul 25

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

GlobeNewswire
·
Jul 21

Successful Commercial Launch of Ryoncil®

GlobeNewswire
·
Jul 18

MSC Income Fund Is Maintained at Neutral by UBS

Dow Jones
·
Jul 16

UBS Adjusts MSC Income Fund Price Target to $16.50 From $15.50, Maintains Neutral Rating

MT Newswires Live
·
Jul 16

Press Release: Bonus Biogroup Appoints Renowned Cell Therapy Leader, Professor Edwin M. Horwitz, MD, PhD, to its Advisory Board

Dow Jones
·
Jul 14

Press Release: MSC Income Fund Announces Second Quarter 2025 Private Loan Portfolio Activity

Dow Jones
·
Jul 10

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

GlobeNewswire
·
Jul 08